{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:03Z","timestamp":1787071263279,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim is to report corneal melting following intrastromal injection of antivascular endothelial growth factor (anti-VEGF), bevacizumab, for pre-existing corneal neovascularization. A 68-year-old male with a history of failed bilateral penetrating keratoplasties due to scarring from childhood measles and trachoma underwent right eye superficial keratectomy, intrastromal bevacizumab, and amniotic membrane transplant to control the neovascularization in an overseas center. A week later developed corneal melting. In conclusion, anti-VEGF can be used in controlling corneal neovascularization, albeit, is associated with risks such as delayed epithelial healing and corneal melting, particularly in those with limbal stem cell deficiency.<\/jats:p>","DOI":"10.4103\/ojo.ojo_344_24","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:00:15Z","timestamp":1750748415000},"page":"205-207","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Corneal melting following intrastromal injection of bevacizumab for corneal neovascularization"],"prefix":"10.4103","volume":"18","author":[{"given":"Muna Salim","family":"Al-Ruhaili","sequence":"first","affiliation":[{"name":"Ophthalmology Residency Program, Oman Medical Specialty Board, Muscat, Sultanate of Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham Hilal","family":"Al-Mahrouqi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Al-Nahdha Hospital, Ministry of Health, Muscat, Sultanate of Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"R1-20250628","doi-asserted-by":"crossref","first-page":"15","DOI":"10.22336\/rjo.2019.4","article-title":"Corneal neovascularization: Updates on pathophysiology, investigations & management","volume":"63","author":"Sharif","year":"2019","journal-title":"Rom J Ophthalmol"},{"key":"R2-20250628","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40662-017-0094-6","article-title":"Therapeutic approaches for corneal neovascularization","volume":"4","author":"Feizi","year":"2017","journal-title":"Eye Vis (Lond)"},{"key":"R3-20250628","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.12998\/wjcc.v11.i30.7337","article-title":"Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis","volume":"11","author":"Lai","year":"2023","journal-title":"World J Clin Cases"},{"key":"R4-20250628","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1038\/s41433-020-01347-3","article-title":"Intrastromal versus subconjunctival anti-VEGF agents for treatment of corneal neovascularization: A rabbit study","volume":"35","author":"Ucgul","year":"2021","journal-title":"Eye (Lond)"},{"key":"R5-20250628","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00417-019-04519-4","article-title":"Intrastromal bevacizumab in the management of corneal neovascularization: A retrospective review","volume":"258","author":"Gupta","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-20250628","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: An epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"R8-20250628","doi-asserted-by":"crossref","first-page":"733538","DOI":"10.3389\/fmed.2021.733538","article-title":"Epidemiology of corneal neovascularization and its impact on visual acuity and sensitivity: A 14-year retrospective study","volume":"8","author":"Lasagni Vitar","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R9-20250628","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nm0909-993","article-title":"Blocking the path of lymphatic vessels","volume":"15","author":"Skobe","year":"2009","journal-title":"Nat Med"},{"key":"R10-20250628","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-20250628","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/15428877-20100215-07","article-title":"Corneal Melt While Using Topical Bevacizumab Eye Drops","author":"Galor","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R12-20250628","doi-asserted-by":"crossref","first-page":"101618","DOI":"10.1016\/j.ajoc.2022.101618","article-title":"Corneal thinning following bevacizumab intrastromal injection for the treatment of idiopathic lipid keratopathy","volume":"27","author":"Sun","year":"2022","journal-title":"Am J Ophthalmol Case Rep"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_344_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:51Z","timestamp":1787067831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_344_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_344_24","relation":{},"ISSN":["0974-620X","0974-7842"],"issn-type":[{"value":"0974-620X","type":"print"},{"value":"0974-7842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-10-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}